TARRYTOWN, NY—Ronald M. Lombardi, the Chief Executive Officer of Prestige Consumer Healthcare Inc. (NYSE:PBH), executed a series of stock transactions on November 19, as detailed in a recent SEC filing. Lombardi sold a total of 10,875 shares of Prestige Consumer Healthcare common stock, with the sales occurring at prices ranging from $80.37 to $82.64 per share, amounting to approximately $898,240.
In addition to the sales, Lombardi acquired a total of 10,875 shares through the exercise of stock options at prices between $56.11 and $57.18 per share, reflecting a total value of $615,774. Following these transactions, Lombardi's direct ownership stands at 320,952 shares.
These transactions were conducted as part of routine financial management and reflect Lombardi's ongoing involvement with the company. Prestige Consumer Healthcare, known for its over-the-counter healthcare and household cleaning products, continues to maintain its headquarters in Tarrytown, New York.
In other recent news, Prestige Consumer Healthcare Inc. reported a slight decrease in Q2 sales to $284 million, but an increase in earnings per share (EPS) to $1.09, according to recent developments. The company also generated $68 million in free cash flow. Despite supply chain issues impacting the Clear Eyes brand, international growth, particularly with the Hydralyte brand and Canadian portfolio, helped mitigate the overall decline in sales. The company also reduced debt by $40 million, achieving a leverage ratio of 2.7x.
Prestige Consumer Healthcare anticipates Q3 revenue to be around $286 million and has provided guidance for fiscal year revenues between $1.125 billion and $1.140 billion. The adjusted EPS forecast for the full year is expected to be between $4.40 and $4.46. The company's long-term growth is projected at 2%-3%.
Despite facing supply chain challenges and expected store closures in the drugstore channel, the company remains committed to capital deployment strategies, including share repurchases and potential mergers and acquisitions. The company also emphasized its focus on e-commerce expansion, which currently makes up 15% of its revenue, with plans for international growth.
InvestingPro Insights
Recent transactions by Prestige Consumer Healthcare Inc.'s (NYSE:PBH) CEO Ronald M. Lombardi align with the company's strong market performance. According to InvestingPro data, PBH's stock is trading near its 52-week high, with a robust 42.29% price total return over the past year. This upward trajectory is further evidenced by the stock's 27.09% gain over the last six months.
The company's financial health appears solid, with InvestingPro Tips highlighting that liquid assets exceed short-term obligations. This financial stability is complemented by PBH's profitability, as analysts predict the company will remain profitable this year, continuing its trend of profitability over the last twelve months.
Despite the recent insider sales, which are often part of executives' financial planning, PBH's market position remains strong. The company's P/E ratio of 20.18 suggests a reasonable valuation considering its growth prospects. Additionally, an InvestingPro Tip notes that the stock generally trades with low price volatility, which may appeal to investors seeking stability.
For those interested in a deeper analysis, InvestingPro offers 12 additional tips for Prestige Consumer Healthcare, providing a comprehensive view of the company's financial landscape and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.